<SEC-DOCUMENT>0001387131-12-002109.txt : 20120710
<SEC-HEADER>0001387131-12-002109.hdr.sgml : 20120710
<ACCEPTANCE-DATETIME>20120710172220
ACCESSION NUMBER:		0001387131-12-002109
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120710
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120710
DATE AS OF CHANGE:		20120710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16731
		FILM NUMBER:		12956542

	BUSINESS ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		516-961-1911

	MAIL ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>thmd-8k_071012.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/9.6pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; text-align: center; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; text-align: center; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; text-align: center; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported): <U>July 10, 2012</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 21pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>THERAPEUTICSMD, INC.</U></B></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10.1pt">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nevada</FONT></TD>
    <TD STYLE="width: 33%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">000-16731</FONT></TD>
    <TD STYLE="width: 33%; font: bold 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">87-0233535</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
        or other jurisdiction of incorporation)</FONT></P>
        <P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 9.5pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission
    File Number)</FONT></TD>
    <TD STYLE="font: 9.5pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>951
Broken Sound Parkway NW, Suite 320, Boca Raton, FL 33487</U></B></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices and Zip Code)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>(561)
961-1911 </U></B></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 6pt"></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N/A</U></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Former
Name and Address of Registrant)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Wingdings 2">&#163;</FONT>Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TABLE
OF CONTENTS &nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Page</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
7 &ndash; Regulation FD</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; text-align: center">
    <TH><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Item
7.01&#9;</FONT> <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Regulation FD Disclosure&nbsp;</FONT></P>
</TH>
    <TH STYLE="text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></TH>
    <TH STYLE="text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&#9;3</FONT></TH></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
9 &ndash; Financial Statements and Exhibits</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; text-align: center">
    <TH><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Item
9.01 (d)
Exhibits</FONT></P>
</TH>
    <TH STYLE="text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></TH>
    <TH STYLE="text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&#9;3</FONT></TH></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 42pt"></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
7 &ndash; Regulation FD</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
7.01&#9;REGULATION FD DISCLOSURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
July 10, 2012, TherapeuticsMD&trade;, Inc., parent company of vitaMedMD<SUP>&reg;</SUP>, LLC (&quot;vitaMedMD&quot;) (&quot;TherapeuticsMD&quot;
or the &quot;Company&quot;), plans to file up to three Investigational New Drug applications (&quot;INDs&quot;) with the U.S.
Food and Drug Administration this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy
for menopausal women. During the same time period, the Company expects to file additional patents for these products.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information in this Item 7.01 of this Form 8-K (the &quot;Report&quot;) is being furnished and shall be deemed &quot;filed&quot;
for the purposes of Section 18 of the Securities Exchange Act of 1934 (the &quot;Act&quot;), or otherwise subject to the liabilities
of that section. The information in this Item 7.01 of this Report also shall not be deemed to be incorporated by reference into
any filing under the Act except to the extent that we specifically incorporate it by reference.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman Bold,serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Section
9 &ndash; Financial Statements and Exhibits</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
9.01&#9;FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">(d)&#9;Exhibits:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exh.
    No.</FONT></TD>
    <TD STYLE="width: 23%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date</FONT></TD>
    <TD STYLE="width: 66%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.0</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July
    10, 2012</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press
    Release regarding INDs*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Date:
    <FONT STYLE="color: black"><U>July 10, 2012</U></FONT></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">THERAPEUTICSMD,
    INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">/s/Robert
    G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Robert
    G. Finizio, Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"\!
M5@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[V]9UG3]`TG4=<U6;[-IFDV%YJ>H7)4O\`9[&PMY;NZG*)EW$5
MO#)(516=@N$5CQ7Y/R?\%V/^"5:.R/\`M8>&%=&*.K>$_B""KJ2&!SX2.2".
MH)!Z@D<U^LNNZ#IGB/1M5T#5X&N-+UK3KW2M0@2::!IK+4+:6SNHEF@>.:%G
M@GD598G22-B'C=752/Q6N?\`@W6_X),S2R7$G[/7B9Y9I6DD)^./QN.YY&+N
M3_Q7XP"2>%X&<``#CU\JCD#]K_;<LTIQ@DL,LKC0D^16<E5=:K2MMHH\WFSY
MW.GQ0GAUP]#)6N7_`&N6:U,9%NI>*C[*.$@V^K;G425[<K>IZ#_P_:_X)4_]
M'9>%_P#PE/B!_P#,C6WX:_X+<?\`!,+QAXBT+PEX<_:D\-ZIX@\4:QIGA[0]
M-B\+^/(Y=0U?6;V#3M-LHY)O"T,*/=7EQ#`CRRI&K.&=E4$C^33]GW_@GE^R
MAX[_`."[?QF_8C\3_#S4+_\`9P\(:C\3;?0/!*>-O&MG?6<7ASP?I.K:0K^+
M;/7H/%MU]FO[N>9C=:U,9PPBG,D2J@_J)\)_\&_O_!+'P)XK\,>-O#/P!\16
M/B+PAX@T?Q1H-Z_QI^,]Y'::SH.HV^J:7<R6MWX[FM;J*"]M8))+:ZAFMKA5
M:&>*2)W5OJLYR;@W*'AZ53$<1U*^,RZEC\,DL+*ER8B*=&%=NO&2=U^]45)*
M+?+*3/BLCS[CW/%B:M&APO"A@LRJ9;B>>69JK*="HH5IT(N=2G*+C=T_:N-W
M92@E<]*^.?\`P5B^`GP"_;=^%?[!_BWP5\4]5^*7Q<'@'^P?$6@Z5X5F\"V#
M?$76=3T31O[6O;SQ;IVO0&UNM*GEU$6^A792UEMY8!=2.T,?ZN+T'T'KZ>_/
MY\U_$S_P4^GL]+_X.-OV+[V[FM[/3].MOV8+V]O;J9+>UL[.W\?>-9Y+BXGE
M9(888(T>2665E2.&-F9@B<?LK\6?^#B'_@F=\)O&UWX%?XL>*/B%?:5?2:;K
M6M?#3P%K/B'PIIEU`[03$>(;P:19:U;I<;$%]X6;7].<.I2]8>8T7FXWABM/
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MWT[7-2MF<"2WO=)T&^L[N-HY+26>.6/?^L?[-O[5WP#_`&M_`"?$W]GSXH>&
MOB;X.:<6D^HZ)-/#>Z7?>3%.^F>(-$U.UT[6O#^JQPS0S2:;K&G6=VL4\4OE
MF*6-F[,5E&:X*DJV,R[%X:D[+VE:C*$$Y)-)SE:*;3NDW?R//P/$.29G6^KX
M#,\)BJ[4I*E2JJ4I1C+EE*/1I2TT=_*VI]'45\"?M!?\%(_V4_V8_CO\+OV;
M_C%\1M1\,_%SXRR>&E^'WAJR\">-O$L&L_\`"7>)W\&:#YNN^'_#FI:)I:W.
MOHT4S:IJ%JMM%^_FDCME:0>+_M1?\%H/V!OV1O'$OPM^*7QH.H_$NVNH;'5/
M!?P]\+:YX]U3P]<O.D#Q>([_`$*RD\.Z)?1,X,VD:GK-IK,0(9M+`$@BSH9;
MF6)=)8?+\9656BZ\)4Z$Y1=*-^::=M8PM[S5TKJS=]-,1GF481U8XK,<)AY4
M:WL*D:M>FI*J^7EA92;O/F]U-*]G>UC]8Z*^)_VHO^"A'[(O[&-M:3?M'_'/
MPC\/+W4K!=4TOPU<+J6O>,]2TUI[BU2_T_P7X3T[7O%MY92W5G=VL=Y%HAM6
MNK2Z@$P-M.T/YVZ!_P`'(7_!+C7/$$6@S_%OQOX>MYY$AA\3:_\`"+Q_#X>,
MCOM4S-IFBZMJ]I;,V$:\O-)M[2T!\V]GAC!<;8?)<XQ=%XC"Y9CJ]%?\O*>'
MG*+:=I*+2]YP^TE=HQQ/$N08.NL-BLWP-"L[>Y4KQ32DDXMVO9237+W['[U4
M5Y7\,?BYX!^,W@O0?B/\+/&WA[Q[X#\4V4>H>'?%'A;4+75]*U2UD1LF&XMO
M,"SQ2*\4]O-Y4]O<126US%%<*\*?&?P]_P""JW[$WQ+^(_QO^%V@_&FUT_Q1
M^SCH_B77OC+)XM\->)O!/AKP;I/@_P`46_@W7[N7Q3XJT73-!U-;7Q)=VVG1
MMI.IWJ7AD\ZR%Q%@MR4\+B:WMU2P]><L-)0Q$%1JJI0FY*$85*<HJ<).3LKQ
MLWL[G;5S/+Z$*%6KC<-3I8I-X6K*K!0Q$5%3E*C)OWXQB[RV:['Z045^!^O?
M\'(__!+K1/&3>%8?BI\0->TV.[-G-XXT+X1^,KCPE"ZM$KSJ][8:=XCOK)#(
MY%SI?AN_CN%MY);0SQ-`T_ZX_L__`+3'P4_:B\!V'Q/^`OQ+\.?$_P`":@[6
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M[7G[/W[7?@1?B/\`L[_%;PW\3O"OVC['=7.C_:+35-%O3&DR6'B+P]JT%AKV
M@Z@86\Y;/6-.TZ>6(&YMXIK8%AY5\1_^"C7[+'PG_:F\`?L:>./B)J6E?M`?
M$Q?#C^#_``A%X$\9ZA8ZDGBVXU"ST`S>*=/T"Z\,V'VVZTN\C9;S5('MRBM.
M%1UK%83%RQ&(PL<-7>*PL'4Q&']FU6I4E\524'9J"U3?22:=F=$LSR^%&CB9
M8R@L/B*D:-"O[1.E5K3:2I0DKWFKW:LM-4V?>E%4WDF$)*D>9A1\HSM+$`D?
M(=VP$L!L^;&"!G(^#=4_X*2_LIZ)^V!;?L'ZK\1-1@_:;OY]-MK3P,/`?C=]
M/DDU?P;'X^T__BL(O#\G@]1/X6E74"C:X)(WVVTIBG;RQ%&A7Q"FZ-&=5TH>
MTJ*"YG"G%KGG*VT873D_-6NVC7$XS"X-1>)KTZ,:E6G0IRJ2Y8U*M7^'3@];
MRELE;H^Q]7_$/XM_"GX2V.GZG\4?B+X(^'.G:M>MINE:AXY\6Z!X4L=1OXX3
M<R65E=Z_J&GVUU=I;AIFMH)9)_+1Y!&41F'?Z3J6GZQI>GZMI-Y:ZCI>J6=O
MJ&FZC8W,-Y97]A>1+<6=[9W=L\MO<VMW;R1W%O<02/%-#(DD;LK`G^(O_@YM
M_;._9_\`C%IOP_\`V7_A]XPN]8^-/P!^-.O3?%+PS)X4\4Z;::##J7@-8;"6
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M]/OM22[ATW,EHBP:C:B!Y%(N)9/)CS)A3]<?#KQSX?\`B?X$\%?$CPK-<7/A
M?Q[X5\/^,O#<UW;/9W4FB>)=)M-9TN6XM)"9+6>2QO('EMW)>&0M&WS*:_)O
M_@KM>?\`!,>V\"_!C5?^"G%I>W_A"/Q9XFM/A4VGVGQ:NY8?$=YI&F7>OK)%
M\)(9;](VTZPLSOUA?LS)!BSWW;^1/^G7PA'@33/@W\+H?A8!:_#:S^'G@Z+X
M?Q2M?*;?P-#X?TQ/#2RKK3_VH@BT,62RG4R=10`FZ!NMX/CXFAAHY5E^)IX7
M,(8FI6Q#K5ZB<<)64*DJ*AAXJ\ZDJ48_O8N*5XOEOU]K"XO%5<]S/!U<7EU3
M"T*.'=#"T[RQN';A"K*>*<E&G"G5E)RHRC.7NRCS*-FE[!17XO?M"_\`!>W_
M`()N_LY>*M3\#:]\:K[XA^+=$N19:SI'PB\'ZSXZ@TNY$ACDAN_%%O#I_@J:
M[BD!CFT_3_$=UJ%NT<BSVBN4%>W_`+('_!6S]AO]MK7/^$0^"7QJL;CX@+')
M,?AUXUT/6?`7C*XBC\]F.D:?XDLK*R\2F**WFFNE\*ZGKIL(HW^WFVECE1:G
MDF<T\.L54RG'T\.X*K[66'FHJC)755NSM!J[3ZKU1I3XDR"MBG@J>;X">)4W
M2=-8B%_:II.DG>SJ)NUKVOU/TRHKP_XX?M`_"C]G#X>:[\5OC9\0/#_PX^'_
M`(=\L:IXD\17"PVL<MQA;6RM+>%9K[4M2NY/DLM-TRVO]1O')6"REVL5_(C2
M?^#C[_@EO?\`B8Z#>?&#QQH^G"9X$\7:G\'?B)%X8E(D""8"VT&[\200;B?W
MU]X=LU5%,TR1P%9VRP>5YGF%*=?`Y?B\51IM)U:-)RB]N:VSO"]I)I-.RZHU
MQV>Y1E=6%',<PPN"JSC&2IUZU.,K2:46U&4K*5[Q>S5WT=OWCE<1QNY&0JDX
MXY]AD@9^IQ7RSX;_`&P?V<_%7QFUG]GW0OB7I-W\6M"O-8L-0\'26NJ6E['?
M:"L<NKV4%Q>6,&GWMU8PR?:9K:SNYYA:QS70C,,4LB^@_!WX]?"']HGP38?$
M3X)?$GPG\3O!&HR>7;^(?!^K6FK6)F4KYEE=F%C<:=?P[D:XT^^AM;V+<!)&
MA^6OX[?V@?#'Q=G_`&[_`-L#XI_!66]A\6?L_P#C_P`0?%^Y?3Y)7O[;2-,\
M8:)H-[<K$KJ+FRM/[;AN-9LW\R*X\/6VL++!)$DD;^ID>34LPJX^EC)U,)B,
M-0BZ%*JO9N6)G/DA3:G'XKM-[*UK/FT/QGQL\6,R\-L)P?F&2992SVAGF>3P
M>/I4E*O6GE6'PT<7C,1@(TDXU*N'HJI5E&I.FN6$G?1G]O*$%%(P054C!!&"
M`1@C@CT(X-03.J$LW``YX&&`!.&.00!V]_J*^0?V+OVK_#7[6_P.\,_%+0Y[
M:RU-HFT7QGX?$BM-X;\7:9#"-4T^8RXD-M,7CU'3)VS]ITF^L;DDM)*L7!_\
M%"_VQ=+_`&0/@5K/BR.:TOOB#XM@G\,_##P](T;->^)KJ!P^KW,*YDDTCPW;
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MP]^)?@#_`(*<?LP2?&`WS^//B7HGC/XN:R-7E>?6?^*X^%/Q5U"WDUV25I&D
MUNZ6-[_4-[F:TN;ZYT]X[>2&X6;[F_X+#^'M&\2_MD_L*>&==T^#5-#\0:C;
M:+K.G709H=0TS5?B+X:LM0LYV5EE\JZM'DMY=DB'RY90I&]L_4RX=P<,WP6!
MGBJTL/6RZIC*\Z:BZBJ4X-RIQNU%.,H.*?,UL[L_G'!>/O&.:>%_$_&N'R#+
M,NSG*^.LMX4R[+<RI55!83,J^7T:-3,?9N4X5%]?I3J0IN5HJ7*Y-1O^FME_
MP5/_`&"]0NH[1/V@O#4(FVB.:^TOQ+:6REB54SSW.B106\9&'::XDC@1#YCR
MJN<?9?@7XJ_#KXH:)!K_`,-_&OA7QUH,Y"Q:QX4US2]>TXOC<4:[TNZNH%D4
M`[XBXDC;*NJ,"*^.[O\`X);_`+!NIZ9-8R?LX^#;;[6DBO<Z?/KMA>Q&<,KR
MV][;:JLUK*H.4DA9'!``(48'Y)_M.?L6_%7_`()KZO+^UA^Q;XQ\3P_#OP]?
MVW_"Q/ASK<]WJMI8:%/?+:1R:GB6$>*/")GE2*87\$NM>'FN3J<.J2AI[V'@
MIX+),;-8?`8C'4,6YJG16-E!T*E25E9RC*3B[;>Z]>A]OC.,O&7@;#PXAXPX
M>X2XAX7H4XXG.L3PA+,X9SDV"E3=6IC%@\;",<9@\-&+E55&I[6"3DX..W]!
M'Q-^.OP]^$5_X>M/&\OB6*?Q/=&ST-=!\#>,_%RW%_\`,$L0WA30M92/4IE2
M>6UTZ0I>WEO:7MS:P36]C=RPY#_M.?`V."[N9OB!HT"V7Q3TWX+30SM-%>I\
M4-8U"STO3O!HL'C%Z^JWES>VTL2Q6[VYL&;4FG%A&UR/'?@Q\0_#'[<7P3^!
M/QK\.7IT&'3/%VD>,M6T40KJ%QIWB'PWIVM:+K?A&YG9K4JD=[JCR0WRQ.9[
M,6]R+5$N#Y>3?_L'?#R_UJ'QE/=W`\<VWQ4C^(T.O_9KI+66&#XV1?&&#3[C
M0QJ(T^?7[2R^W^![#QC)LU6S\.ZOJ=G;PKI][/I8\J-+#4)U:&,4J6(I3G3E
M""3;G&5FI<SC;FWNM[WLV?H,,WXFS:G@LZX666YOP_F^&PN88#%5)NA4^I8O
M`4W"7M*:JRQ%52G9PG&BXI.,G>-G]]V[)-&LL7".-PSC/)/<%@>0>02IZ@D'
M-%1VB>3;Q1KPJKA?O'Y<DKG>`<@$`\#!Z`#`!7GI*%XJS2;M=:VO=)ZO;;?N
MC]#@JG)"ZC"7)!SBMHS<8N:V_FOOKT?4OTQ^@^O]#3ZAE/0`]""WT_SZ?C4M
MV3;LDNK=EVU?370T?1=Y12];H_BN_9._Y6C/VB_^PO\`&G_U7V@5_:>W(`]5
M/\S7\5_[)K`_\'1?[1I'1=8^-08^F/A[H!.?\]:_M0++A>>Q_0DU]KQS>.+R
M&^G_`!C65[Z?9U_`_-_#Q_[%Q"E\4>*LQNNJ?M=+KH_)_J?P2_\`!>GX2ZO\
M>O\`@M3\%?@AH&HIH^J_%GX;?L^_#Z#5Y6*QZ9'XM\:^-]'N]2<(6DECT^QN
M+N:2W$)%SE+4F1+B6)OZ:O`/_!$'_@FKX!^%-C\+KC]F'X=^-Q'I,=AK7CSQ
MGI?]J_$?7+V2U%O?:R/&9F@UKP]?7K>;((O"MUHEI9O(JZ?;6T:^6?P:_P""
MFY!_X.0OV)`<$!/V6#@X(S_PL7QEC(/!.5!&>00",&O[4BI*#@]5]ONDD>G0
MC/Z&NO/,SS+!9)P?0PN+Q&#A+*(5D\/4E0G.3Q<[.4Z?+.<%RNT7)Q\MV<?"
M^397F/$7'%?&X+#8N=/B&6'C]9IQK0A3GA*;GR1J*4(3;LG424U9>]H?PK?L
M3?#;6_\`@FA_P<'7'[)7P[\0ZW>?"KXFS:SX7AL]4NY'_M?P#XH^'5S\4_"B
M:Y#''#!>ZIX-UO28],@U5X_/N#97%Q#]DBU74;2X]4_X+U_&CQ7^U+^W]^S_
M`/\`!,[3_B+IGPS^$FD7_@'5/BSK^KZM#I/AR/Q%X[,>KGQ%XIGOIX+26'P%
MX`2/5/#EA?3QPRZKKUP?/CN+C3KBSZ3X[*!_P=3?`A!\J"V\'$#G`(_9Y\9*
MI]3P!GGG`[XKY%_X+E?`7X?^%O\`@LEX(\?_`+2@\4:1^S3^TU9_">Y\4>,?
M#=V=.U#2=)\,^&]`^$_BZYTS4[C3]3A^T>#CH6A:_K5G;V=_=QZ3JBI)ITES
MJ%C*?K<(J6*X@R;&8Q6QM;@QXV-6G1A6KUL;[*45B%2G.G&IB/8N56,'*+DX
M<ZYF?%8YXK!\,YYE^"C&.$P_'<,"Z4ZDU1IX'VUW1J3BW*C0E.$(2G>*@G:]
MFT?T*_#7]B/_`((<_#?X2Z9\*3I7['/C*SAT2#3=8\8^._&'PW\2?$;Q)=+9
MQPR:]?\`C>ZU;^WK36+F5#>P2Z'=:79Z=/*W]B6&E(8EC_`;X%ZGX2_X)3_\
M%LO!'PL_9Q^*EAX__90_:9U3P9X5N++2/&6F^--%L_#GQ.UNX\/:)9:K?Z5?
MW.G2:]\,?'5OY]AJMXD>OQ^$FG6X+6VO337'ZQ^&_P#@V8_X)G^+]`T?Q5X6
M^(OQR\0^'->TVSU;1-<T3XF>%-2TG5=*OX(Y[&^TR^L_!;VUY97-L\<UM/;.
MT<D+HR,00:Y?X:?\$9?^"0GPA_;`^''PR\-_M#?$2;]I?P)?Z#\8_#_PMU#X
MH^&;S4IU\):]97]A%J5E;^#85^T37%O#-+X>&H6_B&;0?-U"VM(M,47R>/A<
MTR&C#-L/4S?B//:.*R[$T\1@<=@$J2KU:;5/$.%6KB'0>'K77M8.G:,>5^ZK
M'O8G*<\JRR:O1R7AG(EA,QPTL/B\'CW2]O3]I&+H1<)QCB_:03DX7JN^O<_,
MW_@YRU;Q-X;_`."AG[,GB+P1>7=AXRT#X+>#]:\)7^GC=J%EXFTSXJ>*+[0+
MRP!5E:]MM4@L[BW5@RF:-<XX-?J[^P?_`,&ZO[,/ASX8^'/B3^VEI&O?'G]H
M3QY9V_C+QY8Z_P"*O$^E^%_"WB'7HDUB[T>U3P_JFB:WK>KZ;J%U*NN:]K>K
MWB:MJ4=R]I8Z?92F!_@__@N[96>I?\%E_P#@G'87T$=Y8WI_9\M;NTE19H+F
MVG_:+NXI8)XI`R2P31DI+&X97C=E8$$@_P!JR*$CVCC"X'_?`],?G].:Y\]S
MO,,NX5X/P&!Q%6@J^5U<15JTI^SG/#5:\J5*G&I&TN6%IN2BUS72?1/LX?X>
MP&9\7<:XW,<-0Q,L'F=&-.C-*="%54(3DW!OEYTXIWDN:)^+7_!27]FG_@E=
MXX\;?#;]HG_@HIXC\,>&F^'OAW5/!/ABQ\4^.;KPQIOC+3)-8?6QIEUX?\.R
M1^,?&4OA^ZFU![+3-+G:*`:QJ4LMC<&X+1_F#\0]:_X-?_C1X/U+X8:3J?P:
M^%VHZE8S:3X=\?\`@SP'\4/A_K^A:M-#+;V&KQ>*?^$6MK*\FM'5)43Q8UYI
M,Z1^1?6\@VQ'X4M/A;X9_P""H7_!?#]H'X1?MB>,M;M?AY\,_$7Q4\/>"_A^
M^NWNBIK>B_"'7+30/"WPWTFXM[FSNM+@UBQDU/QSK<^DS17^H16NM7-AJ-O+
MJ$]U7])WC?\`X(]?\$DM#^'>M77C/]E3X.^&/"/AS0;Z^USQ+=:CXE\-WFFZ
M-86\UU>WNJ>,+3Q+I^LK%:6\+S7%S<:F^P1"<D%$`QG/#<.PRC!XS-^)GC<5
MAJ&*H4,OQ$:>$IPK_O*:BFU*M4O_`!+IW=DELB*<L9Q&\XQV`R3A:E@<'B*V
M$KUL?1<\:YX>T)R<K.%&%K>Q=XJ-KNR=S\1_^#83XI>)/"GQU_;._9"M/&D7
MCGX6>&[2X^(/@K6-,OUOO#L^H>&/'3^`-4\5^&Y8I)8)K#QYI^JZ!JKW%NYM
M[M-(L+R$LLTQ;\O?V>OV(]8_X*`?\%?/VIOV?Y?%>N^$?A8/C'\;?'/QQO?#
ME^]E?:A\._"7Q8E,6CVBR1RVDNI:GXIUGP_;:?)JMAJ=II=S<?VZEK=MID<<
M7WG_`,&UH^'Z?\%)OVVX_A,D\'PJ3X9>/H_AC:W<]W=75K\/H_CSX<3P;;75
MS?SSW]Q/;^&_[,BFGOY9;ZX<?:;R:2YFD>O+_P#@F7^UQ\.OV5O^"W?[7%E\
M6-:L/#/@GXZ?$;XY_">+Q+JUS!8:-H'B^?XPOXB\*76K7TQ2.TL+Z;2+_0%O
MKB2*UMK[6E-S(BJIKZ[$U,53SKC;$9;2Q,\;+(LLKVKTH?675=&C>K.C&-YU
M&KS3E%WE:7Q:OXVC]6Q>2<$4<YDXX"CQ+F.%K5/:2G&%&523A"-6Z_=2;4='
M90OJHG]1Z?\`!%C_`()E#X<_\*S;]D?X52:4VFG3SXG;2)3\2&9XW4ZBWQ*:
M=O'#:D)'$Z7!UWRT95@2!+$?9*_F2^#?A_QO_P`$2?\`@M7X3_9N\.>--:UO
M]FS]HS5O!VCPV&K3,R:WX)^)U]J'AGP->:K;P&WTUO&/PX\=QOI[:I9VL*W>
ME#4(X+'2[3Q-]DL?[IX-5TUK0WJW]JUEY(N_M8N(VM1;-$LJS"X&(C`T169)
MBVV2)A*K%"&K^'?]L_Q_H?\`P44_X+_?LP_#SX"WD/BWPY\"?%GPQT'6?%^A
MM'JNBW4WP>\9:A\6?B9K=OJ4$CVAT;P_'#-X?2YBG\JZUNS,2/<V^I:-+)\=
MP=F6:9E5S?#YE7Q&-RO^Q\QJXY8FM.I1PV)IX=RIS4JC<:=:-2W+9QD]$TTK
M+[_C;+<JRV&2XK*L-A,#FL<WRV&"^HTX4ZV*PT\1%3BU2M*K3E!>^W&48WNW
M=W/6_P#@X,^.GC']H;]L[]G3_@F=X9\>Z;\.OAS?3^`O$GQ6\1:WJJZ3X;'B
MGQUJUZ-,O?%]U)<6MO+H7P]\&VJ^+X!J-T+:XO\`7IY]B:CIFER2_K'\)/V'
M/^"('PG^$MG\)EM_V.O'EN-'73-<\:_$;Q=\,/%7Q#\278C<-K5[XOO=174M
M/U(73O?V8T,Z99Z-=,6T.TTY(X%@_`3_`(+\_`CP7X0_X*R?!WXG?'^V\5P?
MLS?'WP[\,6\8^)?"LKV.J:78>%+J;P5X_M-(O[FUU")=:\-Z/9^&_%3VLELT
M,MIJ=G%%#([7#VGZS^%O^#:+_@F/XX\/Z+XL\)_$;XZ>(_"WB'3;75-`\0:+
M\4/!^HZ+K&GW<:RP7^G:E:^#)H;RWN5D4Q2QR^6P4^6N,,>_&5,JP_#G#47F
MN:95AZN%^LU)Y92@H8G,)5?WGUBNY1;JTTHJ-%R7+&3M%7:?@82EG..XGXHG
M#),HSG%4<8J%.GG>-=&>&P<8?N9X3#SP]=2IR7,Y8A0B^9*TWT_)OP)J'@7_
M`(),?\%K?ACX;_9>^*>F^/OV4_VE-8\(^'=5T70/&FG>+](M/#WQ-U[4/"=O
MX5U;4M*OKB&ZU#X9^.KRVUSPK=:B\FK)HK117EW=?:]6DU#Z@_X*!2*?^#EO
M]AXKG:]K^SJP(.>OB?QRN#UY^4GC@J5.<D"OHOPE_P`$6/\`@D'\'_VM?AG\
M*-/_`&@OB''^T;H.H:+\6O!?PRU'XL>$;G6[MO!.M:;K-O%?6(\)0Q;KZ:P6
MZCT*ZD@U>]TFUU;4=-@-EID]\GQW_P`%:_&VD?`'_@X!_8Q^,WQ'DDT3X>:5
MH7[//B"_\0W2-#I]KX<L?B3\0-#U[4GNVC*HFAWD,MY?;)E%M:-$9_)M;J(R
M=]'&X#-,RISP2Q5?'0X0S/`XC$5\,\/B<=6C&I6HU'3A%+$5'2:3DHR<VN:[
ML<E?"9IE>33>81P=+"2XRR^KA\+A,9'&4L')RI*M%5;N4*;NXQC+E6J]R+>G
M]MJ@LNX''*,0>>#@XS],#/>OXJ_BF0W_``=@>$^,G^W/AUUYX_X9`T]/IRS;
MB?;FO[.8O$&B7.BP:Y8ZQIMUHMQ8P:G;ZO;7UM-ID^G2PI<P7\5_$[VLMA+`
MRS+=QR-"\+;HY#D&OX8_#WQP\"_M"_\`!T'X3^)?PSU>V\1>#&^)Z^#M-\0:
M?<P7NE:Y-\._V>+[P+JNIZ/?6Q-O?:3/K/AZ]-A>V\LUO=0*DT$\L+(U?*\%
M4*DI\2U8+W,/PWF<*[=G&$YJD_9RYKJ%1R6FTHVLK:'VGB#B,.UPM!U/>K<3
MY34A&-G[14HMJ22TG"+DU)*\;VO?0]M_X.AOV6/@%\*_!OPA^/\`X&^&NA^'
MOB_\8OC3X@A^)7C>REU)]3\70V?@>6>U34H;F^GTZ+R9[6SF4Z?96;$P%9"X
M*[?V?_9&_P""0W_!.6]^!G[-'Q9NOV6?`5Q\1;KX5?![X@W'BJ:^\6M?R^,Y
M_"?AWQ')K[0GQ']C-T=;8W_E?9_LWF?NS"8ODK\Y?^#L5'E_9I_96E5':*+X
MX^)H9I-K>5%*_@&_*1R2$!$9_)E*!B-XBD*Y"/C^B[]C'6=(OOV0/V7;VSU*
MQNK*7]GGX-M'=6]S%+;,L?P\\.0RD3(QB_=2JT4OS?NY5:-]KHRCKS/,\QCP
M-PK;,L="=3&YY1J\N*JQ=2C2K451I32E[U*FFXTX/W8JZBDCFRK*<JJ>('%-
M*MEV"DJ6`R7$TXU,/2;AB)PYZE:'-&ZG.=I5)K6<E>3;/YOO^#LF`P?L]?LD
MAB&/_"X_'`W#/('@6/));)W,2Q(R0,@*``08_P#@M1^V]X]_9U_X)N_L<_L^
M?"/6;_0/'?[3'PD\$V&OZYH]S/:ZOIOPU\-^`?"B:QINF7%FZ7=O?>+]8UC3
M=$,D*R/+HMKXDL=@%X9&M_\`!VA(DG[/?[))1@V/C)XY)X(QGP+'C@@=<'\J
M^3?^"_WP>\91_LM_\$QOVH?#-B][HGPY^%/A#P#XDNQ;_:[/0=4UCPGX,\5>
M#;S4X&$L4=IJ=YHNM6+7<R1VRS00V=T7>_L`GT'#M'#XO`<!T,7RSC_:>?2I
MPJ6<:N(C3JU</3J2?25;E2B]'IHTSYOB>O5H9QXAU,$^2:RG(85JE"7).AAZ
MD\/'$U(1IZZ4I2<I)+E2T>FG[`?\$[O^""_[('P%^!_A.\_:#^#G@?XZ?'?Q
M1HEEJGQ!U+XFZ'9>,O#GA[4]2MH+BX\*^$_#6KK=^'K.TT(;-.EUW['=ZUK%
MW%?WC:LNGWMM86='XX?\&[?[)OC7]H+X/_'/X&:IX@_9B@\'>.+'Q)\0?!OP
MINKC3-*\0Z?I1_M'3SX#D>62;X9ZZ=8LM.@NKG0,Z8='ENUTW2M,U:WL-4A_
M6C]C?]K3X1_MC?`#P-\=?A3K^FWND>)](M+C6]#@U""[U?P7XDB@2/7?"?B.
MUC;[3I^K:+J2W%HT5U!;_:K5(-2M8S8W=M(UGX\?MG?LR?LT>(?AIX4^.'QF
M\&?#CQ!\6_$B>&?`VG:_J207.J7SQ._VV[V;X]$T!)?(M9?$.LFQT"VO[NPL
M;K4H9[Z!)/@JF=\41S7%QEC<P>-MB*-3!*52HH8>,I)Q^JVDE3C!:/V?+!7:
M:NV?H.%X>X0EDV!G/"9:L(EAJM/'N=.E.IB>6$N:6,4U.5253XHNHW)NTHW1
M_+U_P=/)XTT^_P#V);/Q!#XCOOV<[35O%TGBRVT:YE$MYXRBGT%6AFN;TS6:
MZ[)X,.K+X=NM1<W1#:ZUM))&NL>9]U_LZ_"S_@WW_;6^%OA[X>?"7X>_LP2W
M=UI4$$7A*\AL/`7[0NF7DL<,4@O=4O;K2OB7?ZRL[6HGUBVUO6;;4;F)XFU#
M5/)P?U[_`&B/$?[&_CVY\-_LR?M,:U\'/$%W\;M+OM1\(_"KXF7NARW'C>WT
M<V:R7FAZ?JTL3MJ5I)=VS:7<61MM2:X$ITB1Y+2Y,/X-_MA_\&TO[(6K>$O%
M_P`0/V9/'WB_]G#Q9H>D:QXDTK1]9\1S>-OA?#<:38W.JI;3ZAXHN9_%WAVQ
MN3;[3KB^)]2705D>\BTB_BA.G3^WE>;9=B<KRS*LQQF;Y#BL-5QCP&9X"'+A
M\34Q6(A[F,IRY)S2G>*J4N9K9/ENEX&<9'C:&<9QG678').)<)B:&%AC<MQS
MB\3@:6$P[O5P]2;DD^5:QBTI/[+E:W[>_L+_`+`?P&_X)_\`POU?X8_`2TUC
M^QO$GB_5?&NMZSXKOK;5_%&JZAJ$LD=C97VJV5EI<5U8>'=*^SZ'HD36B20V
M,,DMRUS?7VHW%U^8'[#NGV>K?\%;?V_M.OK:&ZM-0T'X@VEU;W$:S6\]E=?$
MCP.+JUFAD#)+%<*T:RHX972,QGY)&%>7?\&T?[8'QU_:!^"WQY^#WQG\3ZKX
M\M/V<?$WP_TGP%XQUR\EU359?#OC>S\9,_A:YURX9K[7+7PO<>"Q-IMWJ-Q?
M:A'8>(+>R69-)LM/M;'US]@PA?\`@KU^WB6.`-)\=`Y]3\2/`0'UY('&:PE@
M<9E^)XMPN/KO$8NA@\-.5?FYWSRJPE"I"=W:7LW"5XM6;[GYSQKBL%FF=?1\
MJ8##>PP&)XYS*FL''F<)..18ZG5H3@VW.$X.NI4VG&I3C=IJ":\EUA-1_P""
M0?[<!U>"&];]CS]H>?[-/%;6]U<6GA*Y%SYK11A&#/JO@>Z1KBSC0S7&H>#]
M6OH[:*\U725C@W_V??#>O_\`!4[]M#6/VEOB#9W47[,?P%U:WTSX6>$]6MIQ
M9^(-3@N8+^QMI+61Y+6:62\L;/Q;XP1@1ONO#VB*L]F@:']N/VL_V7O!7[6?
MP7\3?"+QA&UDFIK'J/AOQ+;6J7>H>$_$]D)#I/B'3X'FMQ-+9O*Z3VHN+<7U
MC/>6+3VXN3.G7?`'X%^"OV=_A-X.^$G@;3S9:%X.TM+-9953[9J]](3<:IK>
MHNAV27^KZE+=ZC<N%10]SY:1PQQI#'Q3SVC+"1KN'+G,L-'!5<5'5RH<KM4<
MEI[6S455^-MV;2WPPO@CG5+B]9)4S&@_!7"YF^,,!PY&565>KGM5\T<EJTHR
MM#)\+B(QQ5/#M^Q<Y1BJ;NT?B;\3H([?_@O5\!(XE6-%^'<XVKD(?+^#?Q9B
M!`8EATPJL7"`%E(>>4M4_P""M;?\9S_\$_<C@>)=%(Y^\/\`A9WACGCIG!J]
M\5BB_P#!>SX#L7`5?AY/U(&0WPB^+B\9Y)RN2%!(&6("HQ'U!^WC^QE\9?VB
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M>6%!.'.U43D*<G@97;OYP&')&<5^-O\`P5(_;W\(_"3X7^*?@+\-/$-EXN^.
M_P`5+"Z\&V^@^&[F'5+OPCI>O%M.O[[68K`W,D&J75A<36/A_2%:VU6ZO[B.
M\5!:VS%OD\NPF)QV/P\,+&3MC*5652*;C3I0G"4JCDDURJ*:;\[ON?U!X@<3
M9/PEP;G&8Y[B:$(4\FKX2GA7**Q>8XC$X"K0I8+!4N:,J]3$59QI>SA&3DWR
MV;/&/^"`.NZI=_`+XT:#+Y@T71_BQ8W^ER2[VB2YU?PAHXU6TCSP`L>EV5S+
M&I&V>^E=@6E!/]`BAG)#$$#'8]0/J>.>GN>W%?G-_P`$N_V7M5_9>_95\/>&
M/%=F;7QUXVU6]^(/C?3V.Y],UC7++3K.RT:5Q@//I.@:9I%C?[%2)=2BOA$F
MPAG_`$<B5@26&.3_`$Q_GUK7/<53KYKC*M%J<9UVE427O6Y8-W2L]8OY'C^!
M^39ED'A9P5EF:T*F&QU/**=6MAZR2KX6&(<L31P]2R7).E3KPA*.CBXN+2::
M2^6W<C]1_C14M%>3=^7W+_(_65[J26MN_O/YMW855F(#''4`[O\`=V@].I/?
M_$\5:I,#T'/!X'(]*EJ^CVTNN]G?\TB9*Z5G9IQ::W5FF_O5U\[GX-?![_@D
MKXP^%_\`P5B^*'_!1ZX^,WAO6?#'C^^\>7%O\,K?PCJEMK6G-XN\.:;X?B6?
MQ))K$MC<+97&GR3NT6E*)TD1%,;!C7[KE_W6["@A5Y_ARPYP3C`ZX)([%L#-
M7#'&>J(>_*J>0<@\CL0#]12E5(P54CT(&/RQ77CL;BLQG2GBZKJ2H86&$HNV
ML:5.5Z:U_ECH>;EN3X+*HUZ>#A*%/%8ZOC\0I2YI3K5[N3YK+[3NG;HEYGX,
M_M3?\$D?&G[1/_!3OX%?M_:;\9/#7AG0/@W_`,*D6_\`AO?>%-4U#6=;7X;>
M(]:\03M;:[!JUM::>=5AUA(;=)=-NC;R1?,9%8,/WB.1&H.`<D=<@-AOH2,\
M<8/.:D$:#HB#Z*!WSZ>O/UYIV!C&!CT[?E3Q6.Q.,C@Z=>?-3P%'ZMA8?\^Z
M"?/R?^!N4NNY6`RG!Y;5QU;"P<*F8XCZUBY-W]I7Y>3GVT;BDK:[+T/PN^(W
M_!*'QGXP_P""N_P^_P""D\/Q?\-67A?P;'HD4_PMG\+ZD^N7O]E_#C6_`C&/
MQ*FK"QA+S:O#J)W:3(B11O#O+D-7W)^W7^P-\!OV_O@Y=?"7XW:1,3:W$FI>
M!_'.BI:VOC#X?>(S:M:KK7A_4YK:Y$<5Q$$@U?29XFTK6+6.."]A5X;.ZL_N
MORT_N)V_A';..W;)QZ9/J:4JIX*@CT(%;U,WS&I6P.)6)G2Q&74*6&PE6D^6
M5.A0BHP@]'=<MXRUU3:.:GP_E<*694*F%A7P^:XEXS%TJOO1GB)*\Y]+7FE*
M-MFNY_&]9?\`!`__`(*E?!I+KX>_LQ?\%0=9\*?!&:><6^B#XE_'?X8W.G6D
M]RV3!X2\$3Z_X9%^]N(TO+NQU/2GOW5EF=8FPOZ1?\$VO^"$WPH_8R^(;?M%
M?&+XB:G^TG^TUF[N=,\<Z_I\EKX<\(ZEJ<+07^N>'M,UB^UW6=0\5SV\EU8R
M>+=?U:XOH[6YN(]-L],EEFN9_P!_MB?W5X)(^4<$\D].I/)/>EVK_='/7@5Z
M6-XMSS,,/4P^(KX>G"O9XCZMA,/AY8BT5"U6I3IQFXM*\HIV<M;'EX'@?(,O
MQE+&TJ.)J5L/)SPL<1BJU>AA)-W3P^'G)TH-/5-IM:+S/P;_`."@'_!)+Q=^
MV/\`MS_LO_M;Z#\9O#G@C1OV?)OAFVI^"M3\(ZEK6I>(E\"?$^3Q]<_8M5M-
M9TZTL&O;24V$0FM;@Q39E9&0%3^[%OF6(,PVL,`CMN*+N`)`..>"0,\5;*(>
MJJ?JH]_;W/YFE`"]`!]`!V`[>P`^@`[5Y&+S'%X["X/"8F494LOH_5L(HJWL
MJ'-SJFM%>TVW?\CW,#E.#R_%9AC,-&4:V9XB.*Q;;NJF(45"4VNTH146O+[O
MYWO^"D7_``0?\._M8_&4?M3_`+./QFU#]FO]I&>73KO6]<LH-13PYXBUO2+=
MH+#Q7%>^'+S3/$GA+Q?#:Q6MO/KNBW5Y:W$5A;3S:,U\;R\O?E#0_P#@A7_P
M4%^.UQI7A?\`;U_X*:_$#XB_!73;N%]2^&W@CQI\2O$[^*K:UN`PCU"]\?)I
M>AZ?J31*$&J:GX8\7:C9R37.V:Z/[Z7^M#:I&"`1Z8&/RZ4A5<'Y5QUQ@8R.
MG'M7JT.*\\P^&HX2&)ISHT(<E&=?#4*^)H1TTH5ZE.4Z:TV322T5CPL3P+P]
MBL95QD\-6ISQ$^;$4L/BJ]##XEW6M:A3FH3EOJUJ]7J?S^_\$QO^"-M__P`$
MY?VH_CW\;[#XLZ!XL^'WQ.\.^)O!O@3X?Z=X>UO3]7\$^&[_`.(.D>*?#%EJ
M6N:KK6KOKDFD:+I%MH5U<+&DT\X%](Y7S,_SX?L4?L)_!?\`X*$?\%*_^"GO
MP3^,W]KV-I9S_&OQ1X,\7>'KB*#Q!X,\7Q?M!Z-IMEKUD+A)K/48DL]1O=/O
MM(OXY;'4M+N[BUD6.YCT^^L?]`:XA\Y,(B')^=3M`;H0Q)1MV-@3!_A8]PN/
MS$_9+_X)7?!#]D']J7XX?M6_#_Q9\2-8\=?'V'Q7!XNT?Q3JNB7?A?3X_%WC
M>Q\>ZA_8EEI^AV%[`]OK%C#!8R76H7;+8S7<<P9_(<>A@N,,32AGF)S',*SS
M;,L+A:&%Q48J,O:8:M!QC>/14(N$G)2BUHU9V/&S'@;"2K\/X/+L%'^R<#C\
M5B,?AYUI<LZ>(HN*;YI.3M)I+E:DK733M?\`!K5O^#?3_@I=::>_PA\)_P#!
M3S7)OV<W$MBWA35/&OQVTJQCT*:57^Q7/PIL?$.I>!K[]RTL=U"NNV]M>/\`
M,T4"WDJ6O[9?\$R?^"1?P#_X)N:)JFH^&;Z]^)7QK\8:=%8>+OC!XEL+*TU%
MM,@E2=_#O@W2X$F7PQX=DNH[:XU&U%_J.IZU-9V$FMZC=P:=I5KI_P"O"JO.
M%'7DX&21CD_D/R%*%4=%4<`<`#A1A1TZ`<#T'`KSL?Q7GF987ZKB,33C1E%.
M4:&&HX7VDN5+FK>PA3]JY+5\[=WJ[GN9?P5P_EN)6,PF'KNJG>F\3BJV*5)7
MORT57<O96>SA:VEK'Q=^VQ^PE\!OV]O@O?\`P9^.^C75WIBS_P!K>%?%.AM9
MV?B_P%XGBM;JUM_$?A34KVSU""VO3;W5Q:WEG?VM]I>J6-Q<V6H6=Q#,/+_F
MOT__`(($_P#!3_X)+>^`?V5/^"G>K>$/@Q?2S^3H?_"P?CK\*[FRMY6!F:#P
MIX&N/$?A_P"WC+B74;#4=*N+M%BA9XE#.?[(L#D8&#U&.OUHVKQ\J\=.!Q]/
M2LLKXBS;)\,\'A*].>&<U-4,5AZ.*I0E>[G3C6A+V<^THVU2O>RMKG'"&2YY
M7^LXRC5IXEPY)8G!XBM@\1**Y>6,ZE&:<X65FI7?9J[/YZ?^"<__``0A^&/[
M(OQ1@_:/^/?Q-U7]IS]I.UOKG4=(\4>(;6=/"GA75;J$V]WXAT^PUR^UO7?$
M'BN1)ITB\4>(-4DFLY'AN-.TK3[RW@O$^O/^"H/_``2U^$'_``4L^''A_0O%
MFKWG@/XI>`WU"Y^'/Q3TFQMM0O-(75C;?VAH'B#2YFB.N>$]4-K%)=V4=Y97
M5G>)%>65[%'+J5GJ7ZL[$'1%Y.3\HY/KTZ^]!1#C**<=,J#CZ<<5E5S[.*V9
M4\VJ8V=3&T)0]A5<84U1IQ7+[.-.DHP<?9^XDXM-7YDTVC;#<+9'A<JJ9-3P
M%-8"NE+$4Y5*M2=7$)QY<3[6I*4XUHJ*<9)W4DGLK/\`C&\)?\&]/_!1N#2E
M^#7BK_@I;J>D_LU;X[2[\%^%_&GQPU/3+K16\E;BUC^%NIZWH?@;3%F@B!DA
M;6=0M4,TSF&[;Y9_L+]G3_@WTTK]EO\`;Z^#W[4WP@^,UC'\(/A+%HXM/AMX
MC\/ZIJ?C;6K^/X83>"_$NN:IXOCU2WT=+_Q-XKO;_P`6F"Q\/6NGVD&H-86M
MK&ELDDG].X1`<A%!ZY"C.3P3T[BC8G/R+SR?E')R3D\>I)^I->C6XRX@KT:F
M&GBJ*PU6C7I5*%+"4*$*SKRYG*O*E",ZC6R<FWU35SR<-X>\.86>&J0I8JM5
MPM>E6H5\5BZV(K453NU3H\\G""N]&H72=M;(_/S_`(**_L$_#G_@HA^SKJ?P
M*\?ZS?>$[JSUNQ\8>`O'&EVUO?WW@[QEI=IJ%C9ZFVFW+)#JFG7-CJNIZ7JV
MFM-9R7>FW]PMK>V%XEM>P_@C^SC_`,$`/VY?A9\1OA;9>+O^"AEW<?L\_"SX
MB^#_`!K;?#'PGK'Q972==M?"OB>R\1+I`\!W^O:=X.\/)J$MH(A,MSKJ6K2W
M,@M;K?F7^O':O/RKSUX'.>N>*-B9!VKD`@':,@'&0#CH=JY^@]!7#E_$6<9=
M@*N68?%IX"K*I4^JUJ%"O"E5K*/MI49U82J4XU&MHR5K)IZV/2S#A+)<RS"C
MFM?#2IX^C[*/ML/7K4?:PH*U%5HPFO:NFKI<]T[ZKJ?C'_P6)_X)B>*O^"FG
MPU^#/@3PM\6/#_PIN/AEXUU[Q7>:EKWA?4?$L&K1:MX>CT5;.W@T_5=+DMI(
M9`;HR2RS)(@\L+&,S+]YWG[,/PY\;?LOZ%^S)\:=$TCXE^!4^%OA7X;^*=-U
M&S>*PUS^P="T[2?[4LHVE-YI5W'=V<>IZ-=6EQ'J>EWT5K<P7GVNWAEC^JB`
M>H!^H'^>PHVJ1@JN,8Q@8QZ8]*XJF9YC5P>!P4ZZ=#+<14Q6`IQ4J:PV(K3<
MZM6,X-3E*3E)I2=E)]K)=T,BRZ..QN/="-2MF>'HX3'\Z4HUJ&'IPIT8<K5O
M=4%?F33WWU/X\O&G_!N)^U#\$O&WB#Q%_P`$[?V]/%'P9\.Z\\RS:'XB\9?$
M7X;^)K2RED:5;"[\<_"".<^)H+4*L$#7OA?3YA;01(\K>6V_W#]E#_@W-@MO
MB_IWQZ_X*%?M#ZQ^UCXXTJZL]3A\(RWGB;5_#&JZE9,)+?\`X3GQ7XYOKWQ1
MXXTR*0R3+HK6&@Z?/'(EIJ2ZC9?;8=2_J;$<:X"HB@8P`JC&!@8P.PX'H..E
M."J.`J@<\``=3D_F>3[U[E3C3B&IA981XNE"G.G&G*K#"8>.+G"*LX5,4H*M
M*,EO[U]7KU/"I\`<-T\5#%_5:TYTZOMJ5&IBL1+!TYZ>]'"<_L>967*^5)=C
M\3/^"E7_``14^!?_``4)U;0?B.?&_C+X._'+PAX;TSPEX7\<>'KD:KX<3PYH
MMQ=W>C^']4\&7<]M!!IFG7%]J$UD_A:_\/7D,U[=O/+="=U/Y1WW_!!;_@J7
MK>CR_"#Q7_P56\3:O\!KR/\`LZ^T*]\;_'768Y]#41P)8S_#[4?$;:!=6/EN
M5719O$KZ()O*DDM'$0!_L.V)G.U<Y!SM&<CH>G4=O2EVK_='Y"L,%Q7GV`P]
M/"T,72E0I1G[*-?"86N\.YRC)>PE4I2E!1L^5M\RNG=.]^C,.".'\RQ4L;B,
M-7AB*EU6EA\9B:$,0FTVJT*<XQDI/XHI*+3LDD?GY_P3V_X)\_!__@G5\"(?
M@[\*;O5->NM4U9_$_CSQSKRVD6M>-O$TT,-LU[<Q6,*V]AI5A;1)8Z!I,(F_
ML[3XXUN;W4=1GU/5M2X3]GS]A[Q#\%?VTOVAOVHK[Q_I&OZ1\:K+Q!:V/A&U
MT2]L=1T+^V?%'AO7TEN=1EOKF"_$$6B7$+B.UM=TDL#`D%POZ>[5QMVKM`P!
M@8`QC&,8QCC'I2&*(D$QQDCH2BDCIT...@_(>E>5+,L=.>.J3KRJU<PCR8FK
M4UE5CH_?Z736BC:,4DDNSS#@KA[,L1POB,1@E&?!V/EFF01HU)THX3&SPU3"
M2G)1?[V#HUJRDIW;E.[81XV)M.1L7!'((P,$'GJ/>H)A\^<,>,9!P.0>O!X]
M_P#)M4F!Z#\JX;>ZX]X\M_NUMUVV/J^6+23BFE;1W5K:IJSZ-+KL?B;^V)_P
M3+^+G[0O[3L?[1_PM_:*3X+Z[8^$=&\/:1=Z5I?B&'Q5I,]C;:S8W][IGB70
M/$NAWED-1L-8GL)C;")Y+"XO;21_+N&KR)/^"8G_``4#!"M_P4Y^*N\?)O/B
MOXQ[SZ;L?$OEF^\26RS'<QW$FOZ#MB?W%_[Y'O[>Y_,^M&Q.FU<'J-HY_2O=
MH\19E2I4Z+>&J0H0A3H^TPU*I*,(I+E<IQDVM-MMC\7S'P$X!S+,LQS:4.(,
M'C<UQ\LTQ_\`9?%&?Y7A\5CZB49UZN&P&/H4&W#W5)4U-Z.4FT?SY3?\$J?V
MV==4Z9XW_P""E7Q:U/P[=#9J-C_:_P`4]2%W`3MDA:'4OB@]EM*,P(GMYT8X
M!3`.?LC]E'_@E9^SI^S#KEO\09GUGXL_%&(F[A\;?$&/3[PZ7?2JR37V@:(E
MF;73;UQ)(/[3O)M4UR%9IXX=6B@GD@K]1=B'&57C@?*.!QP./8?D*"JD8*J1
MC'('3T^GM66+SS,L73]DZT</3EI/ZK2I4)-=5%P@FKK1IMJW2^IUY%X&^'60
M8^AFU')JF9YG@ZCKX+%\09EFN>U<)75O9U*4LTQN*C^[:O%^S4XNSC)-%:T&
M$D`!P)"`<``@*O*G<V1[EB3W)/-6Z1551A0%'H``/TI:\EN[;_R^_32[W?F?
;KD4U%)[I*_O2GKUM*?O-7VOLM-D%%%%(H__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex-99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; text-align: center">
    <TH STYLE="text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">FOR IMMEDIATE RELEASE&nbsp;</FONT></TH>
    <TH STYLE="text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;SYMBOL: TXMD</FONT></TH></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">July 10, 2012</FONT></TD>
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;TRADED: OTCQB</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>THERAPEUTICSMD, INC.
ANNOUNCES PLANS IN HORMONE THERAPY THAT CONCUR WITH THE RECENT JOINT STATEMENT FROM NAMS, ASRM AND THE ENDOCRINE SOCIETY</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR IMMEDIATE RELEASE &ndash; July 10, 2012
&ndash; Boca Raton, FL &ndash; TherapeuticsMD&trade;, Inc. [OTCQB: TXMD], parent company of vitaMedMD<SUP>&reg;</SUP>, LLC (&quot;vitaMedMD&quot;),
a specialty pharmaceutical company (&quot;TherapeuticsMD&quot; or the &quot;Company&quot;), announced today its plans to file up
to three Investigational New Drug applications (&ldquo;INDs&rdquo;) with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy for menopausal women. During
the same time period, the Company expects to file additional patents for these products.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Robert Finizio, the Company's Chief Executive
Officer, stated, &quot;We are excited at the clarity provided by the recent joint statement of agreement regarding the benefits
of hormone therapy for symptomatic menopausal women issued by the leading medical societies devoted to the care of menopausal women.
We believe the joint statement reaffirms the overall direction for the Company&rsquo;s hormonal platform of providing women with
treatment for their menopause symptoms.&quot; (The joint statement of agreement can be found on the NAMS website at www.menopause.org.)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About TherapeuticsMD</U></B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD&nbsp;is a specialty pharmaceutical
company focused on creating safe and effective therapies exclusively for women. The Company&rsquo;s branded OTC and pharmaceutical
products are designed to improve the health and well-being of women from pregnancy through menopause.&nbsp; vitaMedMD provides
dietary supplements and healthcare products focused on improving women&rsquo;s health, wellness, and quality of life. Questions
may be directed to Daniel A. Cartwright, the Company's Chief Financial Officer, at (561) 961-1911. More information on TherapeuticsMD
is available on its website at www.therapeuticsmd.com. More information on vitaMedMD and its products are available at www.vitamedmdrx.com
and www.vitamedmd.com.</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release shall not constitute an
offer to sell or a solicitation of an offer to buy securities of TherapeuticsMD, Inc. Certain statements in this release and other
written or oral statements made by or on behalf of the Company are &ldquo;forward-looking statements&rdquo; within the meaning
of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management&rsquo;s
expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning
of these laws and include our plans to file up to three INDs, our initiation of Phase III clinical trials if the INDs are accepted
by the FDA, our expectations to file additional patents for these products, and our beliefs regarding the joint statement&rsquo;s
reaffirmation of the overall direction of our Company&rsquo;s hormonal platform. The forward-looking statements are subject to
a number of risks and uncertainties including FDA and market acceptance of the Company&rsquo;s services and projects and the Company&rsquo;s
continued access to capital and other risks and uncertainties identified in the Company&rsquo;s Form 10-K and other filings with
the Securities and Exchange Commission. The actual results the Company achieves may differ materially from any forward-looking
statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the
date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether
as a result of future events, new information or otherwise. </I></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center"># # #</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
